San Diego-based Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, announced the expansion of the company's Clinical and Scientific Advisory Board (CSAB) and the appointment of Debasish Roychowdhury, M.D., who will serve as Seragon's acting chief medical officer.
Roychowdhury has a strong background in research and development, regulatory and commercial operations in the oncology field, having previously served in senior leadership roles at Sanofi, GlaxoSmithKline and Eli Lilly and Co. He joins the founding members of the Seragon CSAB that includes academic scientists Charles Sawyers, M.D., Jose Baselga, M.D., Ph.D., and Ronald M. Evans, Ph.D.
Roychowdhury most recently served as senior vice president of global oncology and head of the global oncology division at Sanofi from August 2009 to September 2013. Prior to that, he served as the vice president for clinical development at GlaxoSmithKline (NYSE: GSK) since 2005. In 2008, he was a member of the team that created GSK's new Oncology R&D Unit. Roychowdhury also served in oncology clinical research and later in regulatory affairs for Eli Lilly and Co. (NYSE: LLY).
During his tenure in industry he was involved in the approval of nine drugs, including, Alimta, Tykerb and Jevtana.
Prior to his role in industry, he served as faculty member at the University of Cincinnati, where he directed a number of clinical programs. He moved to the United States in 1989 where he specialized in internal medicine, hematology and oncology at the University of California at San Francisco. Dr. Roychowdhury received his Doctorate of Medicine from the All India Institute of Medical Sciences, New Delhi.